Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
This invention relates to novel compounds suitable for labelling or already labelled by 18 F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).
1. A compound of formula Ia
formula Ia
wherein
W is —C(U 1 )(U 2 )—C≡CH,
U 1 and U 2 are each independently hydrogen or deuterium, wherein at least one of U 1 and U 2 is deuterium,
A is substituted or unsubstituted phenyl, substituted or unsubstituted furanyl, (C 1 -C 4 )alkyl-, G 4 -(C 3 -C 4 )alkynyl-, G 4 -(C 1 -C 3 )alkoxy-, (G 4 -(C 1 -C 3 )alkyl)phenyl-, or (G 4 -(C 1 -C 3 )alkoxy)phenyl-,
G 1 , G 2 , G 3 and G 4 are independently and individually, at each occurrence, selected from hydrogen, (C 1 -C 4 )alkyl, L, and —(C 1 -C 6 )alkyl-L,
with the proviso that exactly one of G 1 -G 4 is L or —(C 1 -C 6 )alkyl-L,
L is a leaving group, or L is F,
n is an integer from 0 to 6,
m is an integer from 0 to 4,
including all isomeric forms of said compound, including but not limited to enantiomers and diastereoisomers as well as racemic mixtures,
and any pharmaceutically acceptable salt, ester, amide, complex or prodrug thereof.
2. The compound according to claim 1 , wherein A substituted or unsubstituted phenyl, substituted or unsubstituted furanyl, (G 4 -(C 1 -C 3 )alkyl)phenyl, (G 4 -(C 1 -C 3 )alkoxy)phenyl, hydroxy-phenyl, halo-phenyl, methoxy-phenyl, dimethoxy-phenyl, trifluormethyl-phenyl, or ((C 1 -C 4 )alkyl)-phenyl.
3. The compound according to claim 2 , wherein A is substituted or unsubstituted phenyl, (G 4 -(C 1 -C 3 )alkoxy)phenyl, hydroxyl-phenyl, fluorophenyl, methoxyphenyl, or methylphenyl.
4. The compound according to claim 1 , wherein G 1 , G 2 , G 3 and G 4 are independently and individually, at each occurrence, hydrogen, methyl, L, or —(C 1 -C 2 )alkyl-L, with the proviso that exactly one of G 1 -G 4 is L or —(C 1 -C 2 )alkyl-L.
5. The compound according to claim 4 , wherein G 1 , G 2 , G 3 and G 4 are independently and individually, at each occurrence, hydrogen, methyl, L, or -methyl-L,
with the proviso that exactly one of G 1 -G 4 is L or -methyl-L.
6. The compound according to claim 1 , wherein L is halo, mesyloxy, tosyloxy, trifluormethylsulfonyloxy, nona-fluorobutylsulfonyloxy, (4-bromo-phenyl)sulfonyloxy, (4-nitro-phenyl)sulfonyloxy, (2-nitro-phenyl)sulfonyloxy, (4-isopropyl-phenyl)sulfonyloxy, (2,4,6-tri-isopropyl-phenyl)sulfonyloxy, (2,4,6-trimethyl-phenyl)sulfonyloxy, (4-tertbutyl-phenyl)sulfonyloxy, or (4-methoxy-phenyl)sulfonyloxy.
7. The compound according to claim 6 , wherein L is chloro, bromo, mesyloxy, tosyloxy, trifluormethylsulfonyloxy, (4-bromo-phenyl)sulfonyloxy, (4-nitro-phenyl)sulfonyloxy, (4-isopropyl-phenyl)sulfonyloxy, or (2,4,6-tri-isopropyl-phenyl)sulfonyloxy.
8. The compound according to claim 1 , wherein L is not F.
9. The compound according to claim 1 , wherein L is 18 F.
10. A compound of formula Ia
wherein
W is —C(U 1 )(U 2 )—C≡CH,
U 1 and U 2 are each independently hydrogen or deuterium, wherein at least one of U 1 and U 2 is deuterium,
A is aryl, substituted or unsubstituted heteroaryl, (C 1 -C 10 )alkyl-, G 4 -(C 2 -C 4 )alkynyl-, G 4 -(C 1 -C 4 )alkoxy-, (G 4 -(C 1 -C 4 )alkyl)aryl-, (G 4 -(C 1 -C 4 )alkoxy)aryl-, (G 4 -(C 1 -C 4 )alkyl)aryl-, or (G 4 -(C 1 -C 4 )alkoxy)aryl-,
G 1 , G 2 , G 3 and G 4 are independently and individually, at each occurrence, selected from hydrogen, (C 1 -C 4 )alkyl, L, and —(C 1 -C 6 )alkyl-L,
with the proviso that exactly one of G 1 -G 4 is L or —(C 1 -C 6 )alkyl-L,
L is 19 F,
n is an integer from 0 to 6,
m is an integer from 0 to 4,
including all isomeric forms of said compound, including but not limited to enantiomers and diastereoisomers as well as racemic mixtures,
and any pharmaceutically acceptable salt, ester, amide, complex or prodrug thereof.
11. A method for synthesizing a compound of claim 1 , said method comprising reacting a compound according to formula Ia in which L is a leaving group with an F-fluorinating agent in which F is 18 F or 19 F.
12. The method according to claim 11 , wherein said F-fluorinating agent is 4, 7, 13, 16, 21, 24-hexaoxa-1,10-diazabicyclo[8.8.8]-hexacosane K F, KF, HF, KH F 2 , CsF, NaF, or a tetraalkyl ammonium salt of F, wherein F= 18 F or 19 F.
13. A method for synthesizing a compound of formula Ia
wherein
W is —C(U 1 )(U 2 )—C≡CH,
U 1 and U 2 are each independently hydrogen or deuterium, wherein at least one of U 1 and U 2 is deuterium,
A is aryl, substituted or unsubstituted heteroaryl, (C 1 -C 10 )alkyl-, G 4 -(C 2 -C 4 )alkynyl-, G 4 -(C 1 -C 4 )alkoxy-, (G 4 -(C 1 -C 4 )alkyl)aryl-, (G 4 -(C 1 -C 4 )alkoxy)aryl-, (G 4 -(C 1 -C 4 )alkyl)aryl-, or (G 4 -(C 1 -C 4 )alkoxy)aryl-,
G 1 , G 2 , G 3 and G 4 are independently and individually, at each occurrence, selected from hydrogen, (C 1 -C 4 )alkyl, L, and —(C 1 -C 6 )alkyl-L,
with the proviso that exactly one of G 1 -G 4 is L or —(C 1 -C 6 )alkyl-L,
L is 18 F,
n is an integer from 0 to 6,
m is an integer from 0 to 4,
including all isomeric forms of said compound, including but not limited to enantiomers and diastereoisomers as well as racemic mixtures,
and any pharmaceutically acceptable salt, ester, amide, complex or prodrug thereof,
said method comprising:
F-fluorinating a compound of formula V
with an F-fluorinating agent to yield a compound of formula IV,
substituting said compound of formula IV with a compound of formula VI
wherein F is 18 F,
a is an integer from 0 to 4,
B is a leaving group,
W 2 is W,
A 2 is R 12 —O-aryl, R 12 —O-heteroaryl, aryl, heteroaryl, such as furanyl, (C 1 -C 10 )alkyl-, (C 2 -C 4 )alkynyl-, (C 1 -C 4 )alkoxy-, ((C 1 -C 4 )alkoxy)aryl-, or ((C 1 -C 4 )alkyl)aryl-,
R 9 and R 10 are independently and individually, at each occurrence, (C 1 -C 6 )alkyl or hydrogen,
R 11 is (C 1 -C 6 )alkyl or R 12 ,
R 12 is hydrogen,
d is an integer from 0 to 4, and
wherein said F-fluorinating agent is 4, 7, 13, 16, 21, 24-hexaoxa-1,10-diazabicyclo[8.8.8]-hexacosane K F, KF, HF, KH F 2 , CsF, NaF, or a tetraalkyl ammonium salt of F wherein F= 18 F,
with the proviso that the compound of formula VI contains exactly one R 12 .
14. The method according to claim 13 , wherein B is iodo, bromo, chloro, mesyloxy, tosyloxy, trifluormethylsulfonyloxy, or nona-fluorobutylsulfonyloxy.
15. The method according to claim 13 , wherein A 2 is R 12 —O-phenyl, phenyl, furanyl, (C 1 -C 4 )alkyl, (C 3 -C 4 )alkynyl, (C 1 -C 3 ) alkoxy and substituted phenyl.
16. The method according to claim 13 , wherein R 9 and R 10 are independently and individually, at each occurrence, (C 1 -C 4 )alkyl or hydrogen.
17. The method according to claim 13 , wherein R 11 is (C 1 -C 4 )alkyl or R 12 .
18. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.
19. A composition comprising a compound according to claim 9 and a pharmaceutically acceptable carrier or diluent.
20. A composition comprising a compound according to claim 10 and a pharmaceutically acceptable carrier or diluent.
21. A composition comprising a compound according to claim 8 and a pharmaceutically acceptable carrier or diluent.
22. A pharmaceutical or diagnostic agent or imaging agent comprising a compound according to claim 1 .
23. A diagnostic agent or imaging agent comprising a compound according to claim 9 .
24. A kit comprising a sealed vial containing a predetermined quantity of a compound according to claim 8 .
25. A method for detecting the presence of monoamine oxidase in a patient's body, said method comprising:
introducing into a patient's body a detectable amount of a compound according to claim 9 , and
detecting said compound or said composition by positron emission tomography (PET).
26. A method of treatment of a disease of the central nervous system comprising administering to a patient a suitable quantity of a compound according to claim 1 .
27. A compound of formula Ia
wherein
W is —C(U 1 )(U 2 )—C≡CH,
U 1 and U 2 are each deuterium,
A is aryl, substituted or unsubstituted heteroaryl, (C 1 -C 10 )alkyl-, G 4 -(C 2 -C 4 )alkynyl-, G 4 -(C 1 -C 4 )alkoxy-, (G 4 -(C 1 -C 4 )alkyl)aryl-, (G 4 -(C 1 -C 4 )alkoxy)aryl-, (G 4 -(C 1 -C 4 )alkyl)aryl-, or (G 4 -(C 1 -C 4 )alkoxy)aryl-,
G 1 , G 2 , G 3 and G 4 are independently and individually, at each occurrence, selected from hydrogen, (C 1 -C 4 )alkyl, L, and —(C 1 -C 6 )alkyl-L,
with the proviso that exactly one of G 1 -G 4 is L or —(C 1 -C 6 )alkyl-L,
L is a leaving group, or L is F,
n is an integer from 0 to 6,
m is an integer from 0 to 4,
including all isomeric forms of said compound, including but not limited to enantiomers and diastereoisomers as well as racemic mixtures,
and any pharmaceutically acceptable salt, ester, amide, complex or prodrug thereof.
28. A compound according to claim 1 , wherein L is 18 F or 19 F.
29. A compound according to claim 1 , wherein n is an integer from 0 to 3.
30. A compound according to claim 1 , wherein n is an integer from 0 to 2.
31. The compound according to claim 1 , wherein L is a leaving group selected from chloro, bromo, iodo, mesyloxy, tosyloxy, trifluormethylsulfonyloxy, nona-fluorobutylsulfonyloxy, (4-bromo-phenyl)sulfonyloxy, (4-nitro-phenyl)sulfonyloxy, (2-nitro-phenyl)sulfonyloxy, (4-isopropyl-phenyl)sulfonyloxy, (2,4,6-tri-isopropyl-phenyl)sulfonyloxy, (2,4,6-trimethyl-phenyl)sulfonyloxy, (4-tertbutyl-phenyl)sulfonyloxy, and (4-methoxy-phenyl) sulfonyloxy.
32. The method according to claim 25 , wherein said method is for imaging a disease of the central nervous system in said patient.
33. The method according to claim 26 , wherein L is 18 F.
34. The method according to claim 26 , wherein L is 19 F.